Dual-targeted therapy for high-risk metastatic colorectal cancer included in National Health Insurance
NQ Score
0/100
N1 Content Completeness
90
AI Summary (NQ-processed)
In Taiwan, dual-targeted therapy for advanced colorectal cancer patients with the BRAF V600E genetic mutation has been included in the National Health Insurance. This offers new hope to high-risk patients who previously had limited treatment options, with expectations of extended average survival and a roughly 40% reduction in mortality risk.